ClinicalKey AI: What Healthcare Leaders Should Ask Before Buying

Overview: How ClinicalKey AI’s AI-Driven Clinical Decision Support Platform Transforms Point-of-Care Knowledge Access

ClinicalKey AI is Elsevier’s generative AI platform in the Real-Time Clinical Decision Support (CDS) category, designed to answer clinical questions by retrieving and summarising evidence at the point of care. It addresses a knowledge-access bottleneck: relevant information is spread across guidelines, journals, reference books and drug resources, making it difficult to locate and interpret within a consultation. Its conversational interface brings these sources into a single question-and-answer workflow, with linked citations for further review.

The platform uses retrieval-augmented generation, combining semantic search with large language models. Rather than relying on keyword matches alone, it retrieves source material relevant to a question’s meaning and uses that material to generate a concise response. Its clinical knowledge base is refreshed daily, and responses can consider details such as age, comorbidities and current medications when supplied in the prompt. This connects evidence retrieval with the context of the clinical question.

The practical benefits are more direct access to relevant evidence and less switching between reference resources. Linked citations support verification, while a reading assistant helps summarise and explore source material without leaving the workflow. EHR and API connectivity can bring these capabilities closer to existing clinical systems. These features offer a route to more efficient evidence review, although they should not be treated as proof of reduced total workload or improved patient outcomes.

Last checked on October 19, 2026: ClinicalKey AI now includes full-text content and visuals from 13 JAMA Network journals following Elsevier’s October 7 content agreement.

What is ClinicalKey AI?

ClinicalKey AI is Elsevier’s generative AI tool for real-time clinical decision support, providing cited answers to clinical questions about diagnosis, treatment and medication management at the point of care. It is designed for clinicians, residents and healthcare organisations, with mobile access and EHR/API integration options. Its technical approach combines retrieval-augmented generation with a daily-refreshed, copyright-cleared knowledge base of journals, guidelines, medical reference texts and drug information, alongside linked citations and clinician-in-the-loop evaluation.

Intended Use and Limitations

• ClinicalKey AI is developed by Elsevier, part of RELX, providing an established corporate parent rather than a standalone startup ownership structure.

• An October 2026 agreement with JAMA Network adds full-text content and visuals from 13 journals; this is a content partnership, not clinical validation of the AI system.

• Elsevier acquired Wellsheet in June 2026 to connect patient context with clinical evidence; deeper Wellsheet-enabled EHR integration remained described as forthcoming in October 2026.

• Elsevier describes ClinicalKey AI as built to support HIPAA-compliant use, with applicability qualifications; buyers should verify contractual terms and deployment-specific safeguards.

• Elsevier states that ClinicalKey AI encrypts user data in transit and at rest and does not grant cloud providers or third-party AI partners access for training purposes.

• Licensed clinicians review responses for accuracy and bias quarterly and before major releases through Elsevier’s clinician-in-the-loop evaluation framework.

• Responses include linked supporting citations and automated citation validation, enabling evidence verification without establishing that every generated answer is clinically correct.

• Elsevier reports CHAI membership and contributions to its testing and evaluation framework; this does not constitute independent product certification.

• ClinicalKey AI received the MedTech Breakthrough AI Innovation Award for the third consecutive year in 2026; the award is industry recognition, not regulatory clearance.